8.3  -0.59 (-6.64%)		03-18 16:00
Open: 8.85 High: 8.96 Volume: 1,404,044		Pre. Close: 8.89 Low: 8.3 Market Cap: 820(M)

Short term
Mid term
Targets	6-month :	10.81	1-year :	11.6
Resists	First :	9.25	Second :	9.93
Pivot price	8.84
Supports	First :	8.14	Second :	6.78
MAs	MA(5) :	8.5	MA(20) :	8.93
	MA(100) :	9.67	MA(250) :	12.2
MACD	MACD :	-0.4	Signal :	-0.4
%K %D	K(14,3) :	31.9	D(3) :	28.4
RSI	RSI(14): 37.3
52-week	High :	18.89	Low :	6.65

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SPRY ] has closed above bottom band by 11.2%. Bollinger Bands are 38.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	8.97 - 9.01	9.01 - 9.05
Low:	8.2 - 8.24	8.24 - 8.28
Close:	8.23 - 8.3	8.3 - 8.36

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Mon, 16 Mar 2026
Bamco Inc. NY Buys 1,228,532 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat

Sun, 15 Mar 2026
Casdin Capital LLC Purchases New Stake in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat

Fri, 13 Mar 2026
ARS Pharmaceuticals, Inc. (SPRY) reports Q4 loss, beats revenue estimates - MSN

Wed, 11 Mar 2026
ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY) - Seeking Alpha

Mon, 09 Mar 2026
ARS Pharmaceuticals Reports $72.2 Million U.S. Revenue for neffy® in 2025, Announces Phase 2b CSU Data Expected Mid-2026 - Quiver Quantitative

Fri, 06 Mar 2026
What To Expect From ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earni - GuruFocus

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	99 (M)
Held by Insiders	9.301e+007 (%)
Held by Institutions	16.8 (%)
Shares Short	20,220 (K)
Shares Short P.Month	0 (K)

EPS	-8.981e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	-56.1 %
Operating Margin	-163.7 %
Return on Assets (ttm)	-19.3 %
Return on Equity (ttm)	-46 %
Qtrly Rev. Growth	1 %
Gross Profit (p.s.)	604.61
Sales Per Share	1.83038e+008
EBITDA (p.s.)	1.47269e+008
Qtrly Earnings Growth	-0.9 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-85 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	4.34

Dividend	0
Forward Dividend	2.224e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.